NovaBay Pharmaceuticals Inc. (NBY) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
2000 POWELL STREET, SUITE 1150 EMERYVILLE, CA 94608 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 3,130 | 5,362 | 7,504 | 11,952 | 6,937 | 3,183 | |||
| Cash and cash equivalents | 3,130 | 5,362 | 7,504 | 11,952 | 6,937 | 3,183 | |||
| Receivables | 759 | 1,973 | 1,668 | 1,106 | 1,066 | 3,385 | |||
| Inventory, net of allowances, customer advances and progress billings | 2,877 | 3,437 | 3,220 | 608 | 492 | 280 | |||
| Inventory | 2,877 | 3,437 | 3,220 | 608 | 492 | 280 | |||
| Prepaid expense | 149 | 170 | 152 | 165 | 94 | 130 | |||
| Other current assets | 81 | 113 | 144 | 102 | 105 | 279 | |||
| Other undisclosed current assets | 158 | 277 | 482 | 309 | 687 | 1,351 | |||
| Total current assets: | 7,154 | 11,332 | 13,170 | 14,242 | 9,381 | 8,608 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 1,296 | 1,831 | 411 | 436 | 1,252 | ✕ | |||
| Property, plant and equipment | 87 | 119 | 193 | 84 | 110 | 201 | |||
| Intangible assets, net (including goodwill) | (575) | 2,628 | 9,728 | ||||||
| Goodwill | 348 | 4,528 | |||||||
| Intangible assets, net (excluding goodwill) | (575) | 2,280 | 5,200 | ||||||
| Other noncurrent assets | 497 | 489 | 476 | 476 | 477 | 552 | |||
| Other undisclosed noncurrent assets | 575 | ||||||||
| Total noncurrent assets: | 1,880 | 5,067 | 10,808 | 996 | 1,839 | 753 | |||
| TOTAL ASSETS: | 9,034 | 16,399 | 23,978 | 15,238 | 11,220 | 9,361 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 2,646 | 3,804 | 3,137 | 2,417 | 2,109 | 3,806 | |||
| Accounts payable | 1,130 | 1,080 | 1,045 | 302 | 331 | 551 | |||
| Accrued liabilities | 1,516 | 2,724 | 2,092 | 2,115 | 1,778 | 3,255 | |||
| Deferred revenue | 4 | 434 | ✕ | ||||||
| Debt | 1,137 | 105 | 2,339 | ||||||
| Derivative instruments and hedges, liabilities | 3 | ||||||||
| Contract with customer, liability | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 2,398 | ||
| Other undisclosed current liabilities | 495 | 449 | 200 | 416 | 802 | (2,357) | |||
| Total current liabilities: | 4,278 | 4,257 | 3,442 | 2,833 | 5,687 | 3,847 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 246 | 87 | 505 | ||||||
| Liabilities, other than long-term debt | 1,442 | 1,588 | 561 | 382 | |||||
| Deferred rent credit | 184 | ||||||||
| Other liabilities | 198 | ||||||||
| Operating lease, liability | 1,108 | 1,588 | 246 | 87 | 505 | ✕ | |||
| Business combination, contingent consideration, liability | 561 | ||||||||
| Derivative instruments and hedges, liabilities | 334 | ||||||||
| Other undisclosed noncurrent liabilities | 9,558 | (87) | 4,055 | 178 | |||||
| Total noncurrent liabilities: | 1,442 | 1,588 | 10,365 | 87 | 4,560 | 560 | |||
| Total liabilities: | 5,720 | 5,845 | 13,807 | 2,920 | 10,247 | 4,407 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 3,314 | 10,554 | 10,171 | 12,318 | 973 | 4,954 | |||
| Preferred stock | 680 | ||||||||
| Common stock | 112 | 652 | 478 | 418 | 279 | 171 | |||
| Additional paid in capital | 176,101 | 165,081 | 150,900 | 147,963 | 125,718 | 119,764 | |||
| Accumulated deficit | (174,849) | (158,152) | (141,887) | (136,063) | (125,024) | (114,981) | |||
| Other undisclosed equity, attributable to parent | 1,950 | 2,973 | |||||||
| Total equity: | 3,314 | 10,554 | 10,171 | 12,318 | 973 | 4,954 | |||
| TOTAL LIABILITIES AND EQUITY: | 9,034 | 16,399 | 23,978 | 15,238 | 11,220 | 9,361 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 14,726 | 14,404 | 8,421 | 9,934 | 6,599 | 12,508 | ||
| Cost of revenue (Cost of Goods and Services Sold) | (6,831) | (6,623) | (2,776) | (3,970) | (1,738) | (1,503) | ||
| Gross profit: | 7,895 | 7,781 | 5,645 | 5,964 | 4,861 | 11,005 | ||
| Operating expenses | (15,491) | (22,198) | (14,507) | (12,390) | (18,876) | |||
| Operating income (loss): | (7,596) | (14,417) | (8,862) | (6,426) | 4,861 | (7,871) | ||
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | (2,064) | (276) | (1,577) | 605 | 19 | |||
| Interest and debt expense | (18) | |||||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (9,660) | (14,693) | (10,439) | (5,821) | 4,843 | (7,852) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 20 | 4,085 | 4,615 | (5,213) | (14,495) | 1,311 | ||
| Loss from continuing operations before income taxes: | (9,640) | (10,608) | (5,824) | (11,034) | (9,652) | (6,541) | ||
| Income tax expense | (5) | (4) | ||||||
| Loss from continuing operations: | (9,640) | (10,608) | (5,824) | (11,039) | (9,652) | (6,545) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (5,824) | (11,039) | (9,652) | (6,545) | |
| Net loss: | (9,640) | (10,608) | (5,824) | (11,039) | (9,652) | (6,545) | ||
| Other undisclosed net loss attributable to parent | (6) | |||||||
| Net loss attributable to parent: | (9,640) | (10,608) | (5,824) | (11,039) | (9,658) | (6,545) | ||
| Preferred stock dividends and other adjustments | (7,057) | (5,657) | (735) | (829) | ||||
| Other undisclosed net income available to common stockholders, basic | ||||||||
| Net loss available to common stockholders, basic: | (16,697) | (16,265) | (6,559) | (11,039) | (10,487) | (6,545) | ||
| Dilutive securities, effect on basic earnings per share | (1,311) | |||||||
| Net loss available to common stockholders, diluted: | (16,697) | (16,265) | (6,559) | (11,039) | (10,487) | (7,856) | ||
Comprehensive Income ($ in thousands)
| 6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (9,640) | (10,608) | (5,824) | (11,039) | (9,652) | (6,545) | ||
| Comprehensive loss, net of tax, attributable to parent: | (9,640) | (10,608) | (5,824) | (11,039) | (9,652) | (6,545) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.